Tag:
Makena
Latest Headlines
Latest Headlines
KV reports doubt about viability under decree
KV Pharmaceuticals ( $KV.A ) has "substantial doubt" about its ability to "continue as a going concern," according to a financial statement filed last week. In the Form 10-Q, the troubled drugmaker
Compounder questions KV's Makena purity claim
Pharmacy services provider PharMerica Corp. is questioning claims made recently by KV Pharmaceutical ( $KV.A ) that the latter's FDA-approved premature-birth prevention drug Makena provides greater
KV crows over Makena purity as FDA checks claim
Tuesday was a good day for beleaguered KV Pharma ( $KV.A ), known recently for its he-said/she-said lawsuits with a former CEO and its exorbitant price setting of preterm-birth preventer Makena after
Fed up investors sue KV over Makena projections
KV Pharmaceutical ( $KV.A ) investors aren't happy. The company's stock has fallen into the toilet, down to $1 per share from $6.50 in mid-February. Some of that decline is no doubt the consequence of
OB/GYN group says KV's Makena deserves reimbursement
Medical societies aren't exactly backing away from their criticism of KV Pharmaceuticals' ( $KV.A ) pricing on its premature birth preventive Makena . But they are saying their opinions shouldn't be
Will KV's 55% Makena price cut satisfy critics?
Answering a firestorm of criticism--as well as an unusual move by FDA--KV Pharmaceutical took an axe to the $1,500 price on its new prenatal drug Makena, cutting it back by 55 percent. The treatment,
FDA thwarts KV's over-the-top pricing on Makena
Here's a fable about the dangers of overreaching. A pharmaceutical company, armed with exclusive rights to an FDA-approved drug for pregnant women, figures it has a lock on the market. The drugmaker
KV blinks, but Makena pricing tactic common
Feeling the pushback from patients, doctors and Congress over the aggressive pricing of the recently approved Makena--a hormone injection used to prevent premature births--KV Pharma says in an SEC
Payers may balk at Makena pricing, KV says
The public outcry over KV Pharmaceuticals' pricing on its new Makena drug is giving the company pause. KV said in an SEC filing that consumer and physician complaints may interfere with its ability
Senators demand FTC probe of KV's Makena pricing
The fallout from KV Pharmaceuticals' pricing of its new drug Makena has gone beyond complaints from patients and doctors. Minnesota Sen. Amy Klobuchar and Ohio's Sen. Sherrod Brown are calling for a
